These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 34267356)

  • 1. Mineralocorticoid receptor blockers for moderate kidney dysfunction: more merit than ever?
    Mukoyama M; Kuwabara T; Adachi M
    Hypertens Res; 2021 Oct; 44(10):1352-1354. PubMed ID: 34267356
    [No Abstract]   [Full Text] [Related]  

  • 2. Mineralocorticoid receptor antagonist for chronic kidney disease, risk or benefit?
    Huang B; McDowell G; Rao A; Lip GYH
    J Hypertens; 2024 Mar; 42(3):396-398. PubMed ID: 38289999
    [No Abstract]   [Full Text] [Related]  

  • 3. Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis.
    Barrera-Chimal J; Girerd S; Jaisser F
    Kidney Int; 2019 Aug; 96(2):302-319. PubMed ID: 31133455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aldosterone receptor blockade and the role of eplerenone: evolving perspectives.
    Epstein M
    Nephrol Dial Transplant; 2003 Oct; 18(10):1984-92. PubMed ID: 13679471
    [No Abstract]   [Full Text] [Related]  

  • 5. Finerenone: a New Mineralocorticoid Receptor Antagonist Without Hyperkalemia: an Opportunity in Patients with CKD?
    Haller H; Bertram A; Stahl K; Menne J
    Curr Hypertens Rep; 2016 Apr; 18(5):41. PubMed ID: 27115525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases.
    Bauersachs J; Jaisser F; Toto R
    Hypertension; 2015 Feb; 65(2):257-63. PubMed ID: 25368026
    [No Abstract]   [Full Text] [Related]  

  • 7. How is the heart best protected in chronic dialysis patients?: Is there life in the old drugs yet? Mineralocorticoid receptor antagonism for cardiovascular prevention in chronic dialysis patients.
    Mark PB; Taylor AH; McQuarrie EP; Jardine AG
    Semin Dial; 2014; 27(4):328-32. PubMed ID: 24499322
    [No Abstract]   [Full Text] [Related]  

  • 8. Aldosterone blockade: an emerging strategy for abrogating progressive renal disease.
    Epstein M
    Am J Med; 2006 Nov; 119(11):912-9. PubMed ID: 17071154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is there a new dawn for selective mineralocorticoid receptor antagonism?
    Luther JM
    Curr Opin Nephrol Hypertens; 2014 Sep; 23(5):456-61. PubMed ID: 24992570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aldosterone blockade in chronic kidney disease.
    Hirsch JS; Drexler Y; Bomback AS
    Semin Nephrol; 2014 May; 34(3):307-22. PubMed ID: 25016401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mineralocorticoid Receptor Antagonism for Cardiovascular Protection in End-Stage Renal Disease: New Data But the Controversy Continues.
    Georgianos PI; Sarafidis PA; Liakopoulos V; Balaskas EV; Zebekakis PE
    J Clin Hypertens (Greenwich); 2016 Mar; 18(3):197-9. PubMed ID: 26456776
    [No Abstract]   [Full Text] [Related]  

  • 12. [Role of aldosterone in oxidative stress and renal injury].
    Nishiyama A; Kusaka T; Kitajima H
    Yakugaku Zasshi; 2007 Sep; 127(9):1331-7. PubMed ID: 17827915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Evidence Supporting the Use of Mineralocorticoid Receptor Blockers in Drug-Resistant Hypertension.
    Narayan H; Webb DJ
    Curr Hypertens Rep; 2016 Apr; 18(5):34. PubMed ID: 27072827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldosterone receptor antagonism in patients with diabetes and chronic kidney disease: new promises and old problems.
    Patrono C; Volpe M
    Eur Heart J; 2021 Jan; 42(1):14-15. PubMed ID: 33428718
    [No Abstract]   [Full Text] [Related]  

  • 15. [Antifibrotic renal role of mineralcorticoid receptor antagonists].
    Ocello A; La Rosa S; Fiorini F; Randone S; Maccarrone R; Battaglia G; Granata A
    G Ital Nefrol; 2019 Jul; 36(4):. PubMed ID: 31373464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Aldosterone exacerbates chronic renal insufficiency].
    Kristensen KE; Egfjord M
    Ugeskr Laeger; 2011 Jan; 173(4):267-70. PubMed ID: 21262170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of cardiovascular risk in chronic kidney disease by mineralocorticoid receptor antagonism.
    Epstein M
    Lancet Diabetes Endocrinol; 2015 Dec; 3(12):993-1003. PubMed ID: 26429402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal Dysfunction Induced by Kidney-Specific Gene Deletion of
    Ueda K; Nishimoto M; Hirohama D; Ayuzawa N; Kawarazaki W; Watanabe A; Shimosawa T; Loffing J; Zhang MZ; Marumo T; Fujita T
    Hypertension; 2017 Jul; 70(1):111-118. PubMed ID: 28559392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mineralocorticoid receptor antagonists and cardiovascular mortality in patients with atrial fibrillation and left ventricular dysfunction: insights from the Atrial Fibrillation and Congestive Heart Failure Trial.
    O'Meara E; Khairy P; Blanchet MC; de Denus S; Pedersen OD; Levesque S; Talajic M; Ducharme A; White M; Racine N; Rouleau JL; Tardif JC; Roy D;
    Circ Heart Fail; 2012 Sep; 5(5):586-93. PubMed ID: 22798522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mineralocorticoid-receptor signalling in vascular smooth muscle.
    Wu J; Luft FC
    Nephrol Dial Transplant; 2013 Jun; 28(6):1360-2. PubMed ID: 23439586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.